BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 194 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q2 2021. The put-call ratio across all filers is 1.06 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $141,600 | -1.5% | 20,000 | 0.0% | 0.04% | +2.6% |
| Q2 2023 | $143,800 | -13.8% | 20,000 | 0.0% | 0.04% | -22.4% |
| Q1 2023 | $166,800 | -27.4% | 20,000 | 0.0% | 0.05% | -33.8% |
| Q4 2022 | $229,600 | -15.9% | 20,000 | 0.0% | 0.07% | -20.4% |
| Q3 2022 | $273,000 | +28.8% | 20,000 | 0.0% | 0.09% | +36.8% |
| Q2 2022 | $212,000 | -34.8% | 20,000 | 0.0% | 0.07% | -23.6% |
| Q1 2022 | $325,000 | +17.3% | 20,000 | 0.0% | 0.09% | +17.1% |
| Q4 2021 | $277,000 | -3.5% | 20,000 | 0.0% | 0.08% | -11.6% |
| Q3 2021 | $287,000 | -9.2% | 20,000 | 0.0% | 0.09% | 0.0% |
| Q2 2021 | $316,000 | +55.7% | 20,000 | 0.0% | 0.09% | +104.8% |
| Q1 2021 | $203,000 | +36.2% | 20,000 | 0.0% | 0.04% | +27.3% |
| Q4 2020 | $149,000 | +186.5% | 20,000 | +33.3% | 0.03% | +153.8% |
| Q3 2020 | $52,000 | +8.3% | 15,000 | +50.0% | 0.01% | +18.2% |
| Q2 2020 | $48,000 | +140.0% | 10,000 | 0.0% | 0.01% | +83.3% |
| Q1 2020 | $20,000 | – | 10,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DG Capital Management, LLC | 1,186,726 | $4,076,000 | 2.45% |
| Sarissa Capital Management LP | 4,861,000 | $16,697,000 | 1.97% |
| Ghost Tree Capital, LLC | 1,950,000 | $6,698,000 | 1.94% |
| ORACLE INVESTMENT MANAGEMENT INC | 2,525,857 | $8,676,000 | 1.14% |
| Eversept Partners, LP | 1,143,211 | $3,926,930 | 0.87% |
| DAFNA Capital Management LLC | 749,051 | $2,573,000 | 0.84% |
| KNOTT DAVID M | 397,361 | $1,365,000 | 0.80% |
| Parkman Healthcare Partners LLC | 800,740 | $2,751,000 | 0.73% |
| ACUTA CAPITAL PARTNERS, LLC | 660,000 | $2,267,000 | 0.62% |
| Formidable Asset Management, LLC | 578,200 | $1,949,000 | 0.57% |